PMID- 38266348 OWN - NLM STAT- MEDLINE DCOM- 20240301 LR - 20240301 IS - 1878-5905 (Electronic) IS - 0142-9612 (Linking) VI - 306 DP - 2024 Apr TI - Platelet-derived drug delivery systems: Pioneering treatment for cancer, cardiovascular diseases, infectious diseases, and beyond. PG - 122478 LID - S0142-9612(24)00012-7 [pii] LID - 10.1016/j.biomaterials.2024.122478 [doi] AB - Platelets play a critical role as circulating cells in the human body and contribute to essential physiological processes such as blood clotting, hemostasis, vascular repair, and thrombus formation. Currently, platelets are extensively employed in the development of innovative biomimetic drug delivery systems, offering significant enhancements in circulation time, biocompatibility, and targeted delivery efficiency compared to conventional drug delivery approaches. Leveraging the unique physiological functions of platelets, these platelet-derived drug delivery systems (DDSs) hold great promise for the treatment of diverse diseases, including cancer, cardiovascular diseases, infectious diseases, wound healing and other diseases. This review primarily focuses on the design and characteristics of existing platelet-derived DDSs, including their preparation and characterization methods. Furthermore, this review comprehensively outlines the applications of these materials across various diseases, offering a holistic understanding of their therapeutic potential. This study aimed to provide a comprehensive overview of the potential value of these materials in clinical treatment, serving as a valuable reference for the advancement of novel platelet-derived DDSs and their broader utilization in the field of disease treatment. CI - Copyright (c) 2024 Elsevier Ltd. All rights reserved. FAU - Zhu, Yalan AU - Zhu Y AD - Department of Pharmacy, Jinhua Municipal Central Hospital, Jinhua, Zhejiang, 321000, China. FAU - Xu, Lingling AU - Xu L AD - Academy of Medical Engineering and Translational Medicine, Medical College, Tianjin University, Tianjin, 300072, China. FAU - Kang, Yong AU - Kang Y AD - Academy of Medical Engineering and Translational Medicine, Medical College, Tianjin University, Tianjin, 300072, China. FAU - Cheng, Qinzhen AU - Cheng Q AD - Department of Pharmacy, Jinhua Municipal Central Hospital, Jinhua, Zhejiang, 321000, China. Electronic address: cqz2543507560@163.com. FAU - He, Yiling AU - He Y AD - Department of Pharmacy, Jinhua Municipal Central Hospital, Jinhua, Zhejiang, 321000, China. Electronic address: hyl970308@163.com. FAU - Ji, Xiaoyuan AU - Ji X AD - Academy of Medical Engineering and Translational Medicine, Medical College, Tianjin University, Tianjin, 300072, China; Medical College, Linyi University, Linyi, 276000, China. Electronic address: jixiaoyuan@tju.edu.cn. LA - eng PT - Journal Article PT - Review DEP - 20240120 PL - Netherlands TA - Biomaterials JT - Biomaterials JID - 8100316 SB - IM MH - Humans MH - *Cardiovascular Diseases/drug therapy MH - Drug Delivery Systems MH - Blood Platelets/physiology MH - *Neoplasms/drug therapy MH - *Communicable Diseases/drug therapy OTO - NOTNLM OT - Disease treatment OT - Platelet OT - Platelet-derived drug delivery systems OT - Targeted delivery COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/01/25 00:42 MHDA- 2024/03/01 06:44 CRDT- 2024/01/24 18:01 PHST- 2023/11/14 00:00 [received] PHST- 2024/01/14 00:00 [revised] PHST- 2024/01/20 00:00 [accepted] PHST- 2024/03/01 06:44 [medline] PHST- 2024/01/25 00:42 [pubmed] PHST- 2024/01/24 18:01 [entrez] AID - S0142-9612(24)00012-7 [pii] AID - 10.1016/j.biomaterials.2024.122478 [doi] PST - ppublish SO - Biomaterials. 2024 Apr;306:122478. doi: 10.1016/j.biomaterials.2024.122478. Epub 2024 Jan 20.